SYDNEY, Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its ...
Kazia Therapeutics (KZIA) announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 1,333,333 of the company’s American Depositary Shares, each ...
Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with ...
Kazia Therapeutics (Nasdaq: KZIA), an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration that accelerated approval for its brain cancer drug, paxalisib ...
SYDNEY - Kazia Therapeutics Limited (NASDAQ: KZIA), a small-cap biotech company ($13.5M market cap) specializing in oncology drug development, has recently concluded discussions with the U.S. Food and ...
1 Day KZIA -41.61% DJIA -0.19% Russell 2K -0.03% Health Care/Life Sciences -0.90% ...
Kazia Therapeutics stock retreated Tuesday after the FDA said it could consider standard, but not accelerated, approval for the company's brain cancer drug. Shares of the oncology-focused drug ...
SYDNEY, Dec. 31, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of ...
Kazia plans to outline a regulatory and clinical path forward for paxalisib by January 2025. Get Real-Time News and Alerts for Your Portfolio Kazia Therapeutics Limited KZIA stock is trading lower ...
Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback